PharVision Advisers’s Hologic HOLX Stock Holding History

PharVision Advisers’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,803	Closed	-$507K	–	346
2025 Q4	$507K	Buy	6,803 +3,539	+108%	+$259K	0.26%	40
2025 Q3	$220K	Buy	+3,264	New	+$217K	0.12%	427

Other funds holding HOLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PharVision Advisers's HOLX Position: Q1 2026 in Review

PharVision Advisers sold out of Hologic (HOLX) in Q1 2026, closing a stake of 6,803 shares — an estimated $507K sold.

PharVision Advisers first reported a position in HOLX in Q3 2025 and held it in 2 quarters. The position peaked at $507K in Q4 2025. 704 funds tracked by Wall St. Rank hold HOLX as of Q1 2026.

PharVision Advisers reported no remaining Hologic position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 6,803 Hologic shares in Q1 2026, an estimated $507K.
PharVision Advisers first reported a position in Hologic in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Hologic position peaked at $507K in Q4 2025.
704 funds tracked by Wall St. Rank held Hologic as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.